Skip to content

2020 European Wearable Remote Patient Monitoring Technology Innovation Leadership Award Publication

Publication - 17 November 2020

Frost & Sullivan: Sensium enhances patient outcomes with wireless monitoring tool

Based on its recent analysis of the European wearable remote patient monitoring market, Frost & Sullivan recognizes TSC Connected Care, a division of The Surgical Company Group with the 2020 European Technology Innovation Leadership Award for the Sensium System. With its technical excellence, superior performance, and potential to significantly improve the standard of care, Sensium earns Frost & Sullivan’s 2020 Technology Innovation Leadership Award in the European wearable remote patient monitoring market. 

2020 European Wearable Remote Patient Monitoring Technology Innovation Leadership Award

Frost & Sullivan, November 2020

Healthcare systems worldwide are trying to cope with an aging population and a rising number of patients suffering from long-term, chronic conditions. This puts burdens on healthcare systems, most of which occur due to adverse events. Moreover, disruptions to healthcare access is increasing due to the current pandemic, spurring the adoption of digital monitoring solutions that i.e. remotely collect and store biometric readings. These recent innovations in wireless and remote patient monitoring have shown promising evidence in improving patient outcomes. However, there is a lot of noise in the market and a lack of evidence-based publications on product efficacy and outcomes. With its technical excellence, superior performance, and potential to significantly improve the standard of care, Sensium earns Frost & Sullivan’s 2020 Technology Innovation Leadership Award in the European wearable remote patient monitoring market. 

System performance and Evidence Base

The report notes that the Sensium system acts as a clinical early warning system for acute care; the System detects and notifies nurses and physicians on several, helping prevent the advent of hospital-based adverse events, the cost of which currently amounts to GBP 2.5 billion per year. Sensium differentiates itself from competitors due to the product’s robust evidence base and real-word deployments.

 

Hospital @ Home service

The report noted the development of a Hospital@ Home solution, which will help hospitals reach beyond traditional infrastructure by providing oversight of managed home care providers, enabling additional capacity. The model is expected to yield significant growth to the company in the future.

 

Commercial model and cost savings

Frost & Sullivan notes that the Sensium System’s ability to support early detection of any deterioration coupled with an outcome-centric approach leads to additional hospital capacity. Sensium leverages a technology-enabled care delivery model to decrease the cost of care to patients, payers, and providers. The company’s innovative Sensium solution cost-effectively optimizes patient outcomes by supporting early intervention. The Surgical Company – Connected Care’s commercial model can be customized based on targets set by the hospitals. Recently the company has taken the route of value-based contracting by identifying and enabling providers’ pain points through its product use. Remunerations are tied to hospital performance.

Don’t miss out!

Subscribe to our monthly newsletter containing the latest updates and developments of The Surgical Company